Zusammenfassung
Die strikte Trennung der demenziellen Alterserkrankungen in die beiden häufigsten Ätiologien Alzheimer Demenz (AD) und vaskuläre Demenz (VD) folgt oder erfolgt nach pathophysiologischen Erkenntnissen und klinisch operationalen Kriterien. Sie ist aber auf der Grundlage neuerer Forschungsergebnisse in dieser kategorischen Form zu relativieren. Das Risiko, eine neurodegenerative Demenz im Alter zu entwickeln, ist polygenetisch determiniert und alterskorreliert, wobei die Ablagerung von β-Amyloid-Peptiden als wesentlicher Endpunkt in der Pathophysiologie der AD verstanden wird. Für die VD wurden insbesondere mikroangiopathische inkomplette Infarkte auf der Grundlage einer Fibrohyalinose als pathophysiologisch bedeutsam erkannt. Kontrovers diskutiert wird die Koinzidenz von genetisch determinierten Risikofaktoren für die AD oder die VD. Gut belegt sind Interaktionen von perivaskulären Mediatoren und den die Zirkulation beeinträchtigenden Faktoren für die beiden Formen der Altersdemenz. Aus diesen und weiteren neuropathologischen und therapeutischen Erkenntnissen wird die Hypothese abgeleitet, dass die jeweiligen spezifischen Ätiopathogenesen von AD und VD miteinander interagieren und die Phänomenologie der demenziellen Entwicklung von individuellen vaskulären Risikofaktoren modifiziert wird. Sowohl eine kategoriale Trennung von AD und VD als auch die Vorstellung der AD als eine Form der VD sind dagegen wenig überzeugend.
Abstract
Alzheimer's dementia (AD) and vascular dementia (VD) are the two major forms of dementia in the elderly. They have been separated categorically on the basis of pathophysiological findings and clinical operationalized criteria. However, this strict separation has to be reevaluated in the light of recent data. The risk to develop a neurodegenerative dementia in old age is determined by various susceptibility genes and correlated with aging. In AD, the current understanding of pathophysiology focuses on the amyloid cascade hypothesis as the major endpoint of the complex cellular pathology. In VD, incomplete microangiopathic infarcts due to fibrohyalinosis are regarded as the major pathophysiological event. A controversial discussion exists about the coincidence or interaction of genetically determined risk factors of AD and/or VD. Further interactions between AD and VD exist with regard to perivascular mediators and those factors which impair cerebral blood flow. Based on these and other recent neuropathological and therapeutic findings the hypothesis is proposed that the two specific etiopathologies of AD and VD interact to precipitate clinical dementia in the individual and that the individual phenomenology of these dementias is modified by vascular risk factors. Neither, a categorical separation of AD and VD nor the recent idea to regard AD as a distinct form of vascular dementia, do appear convincing.
Literatur
1
MacKhann G, Drachmann D, Folstein M. et al .
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of departement of health and human service task force on Alzheimer's disease.
Neurology.
1984;
34
939-944
2
Roman G C, Tatemichi T K, Erkinjuntti T. et mult al .
Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.
Neurology.
1993;
43
250-260
3
Zekry D, Duyckaerts C, Belmin J. et al .
Alzheimer's disease and brain infarcts in the elderly. Agreement with neuropathology.
J Neurol.
2002;
249
1529-1534
4
Hentschel F, Damian M, Kreis M, Krumm B.
Auswirkungen der erweiterten klinischen Diagnostik auf das Diagnosespektrum einer Gedächtnisambulanz.
Gerontologie und Geriatrie.
2004;
37
145-154
5
Bigler E D, Kerr B, Victoroff J. et al .
White matter lesions, quantitative magnetic resonance imaging, and dementia.
Alzheimer Dis Assoc Disord.
2002;
16
161-170
6
Wallin A.
The overlap between Alzheimer's disease and vascular dementia: The role of white matter changes.
Dement Geriat Cogn Disord.
1998;
9
30-35
7 Hentschel F, Kölsch H, Heun R. Molekulargenetische Untersuchungen bei Patienten mit klinisch diagnostizierter subkortikaler vaskulärer Demenz. DFG-Antrag 2003
8
Strittmatter W J, Saunders A M, Schmechel D. et al .
Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.
Proc Natl Acad Sci USA.
1993;
90
1977-1981
9
Panza F, D'Introno A, Colacicco A M. et al .
Vascular risk and genetics of sporadic late-onset Alzheimer's disease .
J Neural Transm.
2004;
111
69-89
10
Huang H M, Kuo Y M, On H Cl.
Apolipoprotein E polymorphism in various dementias in Taiwan Chinese population.
J Neural Transm.
2002;
109
1415-1421
11
McIlroy S P, Dynan K B, Lawson J T.
Moderately elevated plasma homocystein, methylenetetrahydrofolate reductasegenotype, and risk for stroke, vaskular dementia, and Alzheimer disease in Northern Ireland.
Stroke.
2002;
33
2351
12
Bronge L, Fernaeus S E, Blomberg M. et al .
White matter lesions in Alzheimer patients are influenced by Apolipoprotein E genotype.
Dement Geriat Cogn Disord.
1999;
10
89-96
13
Leys D, Pasquir F, Parnetti L.
Epidemiology of vascular dementia.
Haemostasis.
1998;
28
134-150
14
Frank A, Díez-Tejedor E, Bullido M J. et al .
ApoE genotype in cerebrovascular disease and vascular dementia.
J Neurol Sci.
2002;
203 - 204
173-176
15
Traykov L, Rigaud A S, Baudic S. et al .
Apolipoprotein ε 4 allele frequency in demented and cognitively impaired patients with and without cerebrovascular disease.
J Neurol Sci.
2002;
203 - 204
177-181
16
Söderberg M, Edlund C, Kristensson K.
Lipid composition of different regions of the human brain during aging.
J Neurochem.
1990;
54
415-423
17
Svennerholm L, Boström K, Helander C G. et al .
Membrane lipids in the aging human brain.
J Neurochem.
1991;
56
2051-2059
18
Svennerholm L, Boström K, Jungbjer B. et al .
Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years.
J Neurochem.
1994;
63
1.802-1.811
19
Söderberg M, Edlung C, Kristensson K, Dallner G.
Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease.
Lipids.
1991;
26
412-425
20
Zhang Y, Appelkvist E L, Kristensson K. et al .
The lipid composition of different regions of rat brain during development and aging.
Neurobiol Aging.
1996;
17
869-875
21
Mason R P, Shoemaker W J, Shajenko L. et al .
Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol.
Neurobiol Aging.
1992;
13
413-419
22
Terracina L, Brunetti M, Avellini L. et al .
Arachidonic and palmatic acid utilization in aged rat brain areas.
Mol Cell Biochem.
1992;
115
35-42
23
Igbavboa U, Avdulow A, Schröder F, Wood W G.
Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice.
J Neurochem.
1996;
66
1717-1725
24 Cullis P R, Hope M J. Physical properties und functional roles of lipids in membranes. In: Vance DE, Vance J (eds.). Biochemistry of lipids, lipoproteins and membranes. Elsevier, Amsterdam, New York 1991: 1-40
25
Vedie B, Jeunemaitre X, Megnien J L. et al .
A new DNA polymorphism in the 5′ untranslated region of the human SREBP-1a is related to development of atherosclerosis in high cardiovascular risk population.
Atherosclerosis.
2001;
154
589-597
26
Klein J.
Membrane breakdown in acute and chronic neurodegeneration. Focus on choline containing phospholipids.
J Neural Transm.
2000;
107
1027-1063
27
Mulder M, Ravid R, Swaab D F. et al .
Reduced levels of cholesterol, phospholipids, and fatty acids in cerebral spinal fluid of Alzheimer disease patients are not related to apolipoprotein E 4.
Alzheimer Dis Ass Disord.
1998;
12
198-203
28
Lütjohann D, Breuer O, Ahlborg G. et al .
Cholesterol homeostasis in human brain: Evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation.
Proc Natl Acad Sci USA.
1996;
93
9799-804
29
Mori E, Ishii K, Hashimoto M. et al .
Role of functional brain imaging in the evaluation of vascular dementia.
Alzheimer Disease and Associated Disorders.
1999;
13
S91-S101
30
Bartzokis G.
Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer`s disease.
Neurobiol Aging.
2003;
25
5-18
31
Braak H, DelTredici K.
Poor and protracted myelination as a contributory factor to neurodegenerative disorders.
Neurobiol Aging.
2003;
25
19-23
32
Kojro E, Gimpl G, Lammich S. et al .
Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM.
Proc Natl Acad Sci USA.
2002;
98
5815-5820
33
Fassbender K, Simons M, Bergmann C. et al .
Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo.
Proc Natl Acad Sci USA.
2001;
98
5856-5861
34
Wolozin B, Kellman W, Ruosseau P. et al .
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase in-hibitors.
Arch Neurol.
2000;
57
1439-1443
35
Simons K, Ikonen E.
How cells handle cholesterol.
Science.
2000;
290
1721-1726
36
Papassotiropoulos A, Lütjohann D, Bagli M. et al .
24S-Hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia.
J Psychiatr Res.
2002;
36
27-32
37
Panzenboeck U, Balazs Z, Sovic A. et al .
ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells.
J Biol Chem.
2002;
277
42 781-42 789
38
Hatanaka Y, Kamino K, Fukuo K. et al .
Low density lipoprotein receptor-related protein gene polymorphisms and risk for late-onset Alzheimer's disease in a Japanese population.
Clin Genet.
2000;
58
319-323
39
Kang D E, Pietrzik C U, Baum L. et al .
Modulation of amyloid β-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway.
J Clin Invest.
2000;
106
1159-1166
40
Erecinska M, Silver I A.
ATP and brain function.
J Cereb Blood Flow Metab.
1989;
9
2-19
41
Buttgereit F, Brand M D.
A hierarchy of ATP-consuming processes in mammalian cells.
Biochem J.
1995;
312
163-167
42
Davies R E, Miller S, Herrnstadt C. et al .
Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease.
Proc Natl Acad Sci USA.
1997;
94
4526-4531
43
Dyrks T, Dyrks E, Hartmann T. et al .
Amyloidogenicity of βA4 and βA4-bearing amyloid protein precursor fragments by metalcatalyzed oxidation.
J Biol Chem.
1992;
67
18 210-18 217
44
Gabuzda D, Busciglio J, Chen L B. et al .
Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative.
J Biol Chem.
1994;
269
13 623-13 628
45
Frölich L, Blum-Degen D, Bernstein H G. et al .
Insulin and insulin receptors in the brain in aging and in sporadic Alzheimer's disease.
J Neural Transm.
1998;
105
423-438
46
Frölich L, Blum-Degen D, Riederer P, Hoyer S.
A disturbance of the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease.
Ann NY Acad Sci.
1999;
893
290-294
47
Gasparini L, Gouvas G K, Wang R. et al .
Stimulation of β-amyloid precursor protein trafficking by insulin reduces intraneural β-amyloid and requires nitrogen-activated protein kinase signalicy.
J Neurosci.
2000;
21
2561-2570
48
Evans D, Aberle J, Wendt D. et al .
A polymorphism, L162V, in the peroxisome proliferator-activated receptor α (PPARα) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus.
J Mol Med.
2001;
79
198-204
49
Hara M, Wang X, Paz V P. et al .
Identification of three missense mutations in the peroxisome proliferator-activated receptor alpha gene in Japanese subjects with maturity-onset diabetes of the young.
J Hum Genet.
2001;
46
285-288
50
Flavell D M, Jamshidi Y, Hawe E. et al .
Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease.
Circulation.
2002;
105
1440-1445
51
Combs C K, Johnson D E, Karlo J C. et al .
Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists.
J Neurosci.
2000;
20
558-567
52
Schmidt R, Schmidt H, Curb J D. et al .
Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study.
Ann Neurol.
2002;
52
168-174
53
Grimaldi L ME, Casadei V M, Ferri C. et al .
Association of early-onset Alzheimer's disease with an interleukin-1α gene polymorphism.
Ann Neurol.
2000;
47
361-368
54
Kölsch H, Ptok U, Bagli M. et al .
Gene polymorphisms of interleukin-1α influence the course of Alzheimer's disease.
Ann Neurol.
2001;
49
818-819
55
Rogers J.
An IL-1α susceptibility polymorphism in Alzheimer's disease.
Neurology.
2000;
55
464-465
56
Zaremba J, Losy J.
sPECAM-1 in serum and CSF of acute ischaemic stroke patients.
Acta Neurol Scand.
2002;
106
292-298
57
Cheng C Y, Hong C J, Liu H C. et al .
Study of the association between Alzheimer's disease and angiotensin-converting enzyme gene polymorphism using DNA from lymphocytes.
Eur Neurol.
2002;
47
26-29
58
Myllykangas L, Polvikoski T, Sulkava R. et al .
Cardiovascular risk factors and Alzheimer's disease: a genetic association study in a population aged 85 or over.
Neurosci Lett.
2000;
292
195-198
59
Losito A, Kalidas K, Santoni S. et al .
Polymorphism of renin-angiotensin system genes in dialysis patients-association with cerebrovascular disease.
Nephrol Dial Transplant.
2002;
17
2184-2188
60
Vasku A, Soucek M, Tschoplova S, Stejskalova A.
An association of BMI with A (-6) G, M235T and T174M polymorphisms in angiotensinogen gene in essential hypertension.
J Hum Hypertens.
2002;
16
427-430
61
Szolnoki Z, Somogyvari F, Kondacs A. et al .
Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischemic stroke.
J Neurol Neurosurg Psychiatry.
2003;
74
1615-1620
62
Reif A, Schneider M F, Kamolz S, Pfuhlmann B.
Homocysteinemia in psychiatric disorders: association with dementia and depression, but not schizophrenia in female patients.
J Neural Transm.
2003;
110
1401-1411
63
Kessler H, Bleich S, Falkai P, Supprian T.
Homozystein und Demenzerkrankungen.
Fortschr Neurol Psychiat.
2003;
71
150-156
64
Kim N K, Choi B O, Jung W S. et al .
Hyperhomocysteinemia as an independent risk factor for silent brain infarction.
J Neurol.
2003;
61
1595-1599
65
Iadecola C, Gorelick P B.
Converging pathogenic mechanisms in vascular and neurodegenerative dementia.
Stroke.
2003;
34
335-337
66
Honig L S, Tang M X, Albert S. et al .
Stroke and the risk of Alzheimer disease.
Arch Neurol.
2003;
60
1707-1712
67
Ball M J.
White matter lesions, dementia, and ischemic axonopathy (letter).
Alzheimer Dis Assoc Disord.
2003;
17
55
68
Jellinger K, Attems J.
Incidence of cerebrovascular lesions in Alzheimer's disease: a postmortem study.
Acta Neuropathol.
2003;
105
14-17
69
Hentschel F, Kreis M, Damian M, Krumm B.
Mikroangiopathische Läsionen in der weißen Hirnsubstanz: Quantifizierung und Korrelation mit psychologischen Testergebnissen.
Nervenarzt.
2003;
74
55-61
70
Snowdon D A, Greiner L H, Mortimer J A.
Brain infarction and the clinical expression of Alzheimer disease.
JAMA.
1997;
277
813-817
71
Mungas D, Reed B R, Ellis W G, Jagust W J.
The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease.
Archiv of Neurology.
2001;
58
1243-1247
72
Crystal H, Dickson D.
Cerebral infarcts in patients with autopsy proven Alzheimer's disease (abstract).
Neurobiol Aging.
2002;
23 (Suppl1)
207
73
Jernigan T L, Fennema-Notestine C.
White matter mapping is needed.
Neurobiol Aging.
2003;
25
37-39
74
Wardlaw J M, Sandercock P AG, Dennis M S, Starr J.
Is breakdown of the blood-brain barrier responsible for lacunar stroke, leucoaraiosis, and dementia?.
Stroke.
2003;
34
806-812
75
Corey-Bloom J, Thal L J, Galasko D. et al .
Diagnosis and evaluation of dementia.
J Neurol.
1995;
45
211-218
76
Hentschel F, Kreis M, Damian M. et al .
Evaluation des Beitrages der radiologischen bildgebenden Diagnostik bei demenziellen Erkrankungen - ein Vergleich mit der psychologischen Diagnostik.
Fortschr Röntgenstr.
2003b;
175
1335-1343
77
Fazekas F, Schmidt R, Scheltens P.
Pathophysiologic mechanisms in the development of age-related white matter changes of the brain.
Dementia.
1988;
9 (Suppl 1)
2-5
78
Hirono N, Yasuda M, Tanimukai S. et al .
Effects of the Apolipoprotein E4 allele on white matter hyperintensities in dementia.
Stroke.
2000;
31
1263-1268
79
Bronge L, Wahlund L O.
Prognostic significance of white matter changes in a memory clinic population.
Psych Res Neuroimaging.
2003;
122
199-206
80
Schmidt R, Roob G, Kapeller P. et al .
Longitudinal changes of white matter abnormalities.
Neurobiol Ageing.
2000;
21
19-26
81
Scheltens P, Barkhof F, Valk J. et al .
White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease.
Brain.
1992;
115
735-748
82
Schmidtke K, Hüll M.
Neuropsychological differentiation of small vessel disease, Alzheimer's disease and mixed dementia.
J Neurol Sci.
2002;
203 - 204
17-22
83
Barber R, Scheltens P, Gholkar A. et al .
White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging.
J Neurol Neurosurg Psychiatry.
2002;
67
66-72
84
Wallin A, Sjögren M, Edman A. et al .
Symptoms, vascular risk factors and blood-brain barrier function in relation to CT white-matter changes in dementia.
Eur Neurol.
2002;
44
229-235
85
Hargrave R, Geck L C, Reed B, Mungas D.
Affective behavioural disturbances in Alzheimer's disease and ischemic vascular disease.
J Neurol Neurosurg Psychiat.
2000;
68
41-46
86
Marti-Fabregas J, Valencia C, Lopez-Contreras J. et al .
Blood pressure variability in Biswanger's disease and isolated lacunar infarction.
Cerebrovascular Diseases.
2001;
11
230-234
87
Honig L S, Tang M X, Albert S. et al .
Stroke and the risk of Alzheimer disease.
Arch Neurol.
2003;
60
1707-1712
88
Schuff N, Capizzano A A, Du A T. et al .
Different pattern of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD.
J Neurol.
2003;
61
358-364
89
Burggren A C, Small G W, Sabb F W, Bookheimer S Y.
Specifity of brain activation patterns in people at genetic risk for Alzheimer disease.
Am J Geriatr Psychiatry.
2002;
10
44-51
90
DeCarli C, Grady C L, Clark C M. et al .
Comparison of positron emission tomography, cognition, and brain volume in Alzheimer's disease with and without severe abnormalities of white matter.
J Neurol Neurosurg Psychiatry.
1996;
60
158-167
91
Tohgi H, Yonezawa H, Takahashi S. et al .
Cerebral blood flow and oxygen metabolism in senile dementia of Alzheimer's type and vascular dementia with deep white matter changes.
Neuroradiology.
1998;
40
131-137
92
Damian M, Kreis M, Krumm B. et al .
Diskriminante Validität neuropsychologischer Verfahren in der Demenzdiagnostik.
Z Neuropsychol.
2003;
14
271-282
93
Looi J CL, Sachdev P S.
Differentiation of vascular dementia from AD on neuropsychological tests.
Neurology.
1999;
53
670-678
94
Cannata A P, Alberoni M, Franceschi M.
Frontal impairment in subcortical ischemic vascular dementia in comparison to Alzheimer's disease.
Dement Geriat Cogn Disord.
2002;
13
101-111
95
Snowden J S.
Neuropsychological evaluation and the diagnosis and differentialdiagnosis of dementia.
Reviews in Clinical Gerontology.
1999;
9
65-75
96
Pasquir F.
Early diagnosis of dementia: neuropsychology.
Neurology.
1999;
246
6-15
97 Damian M, Kreis M, Krumm B, Hentschel F. Optimized neuropsychological procedures for different levels of dementia diagnostics. J Neurol Sci (in press)
98
Barr A, Benedict R, Tune L, Brandt J.
Neuropsychological differentiation of Alzheimer's disease from vascular dementia.
Int J Geriatr Psychiatry.
1992;
7
621-627
99
Kertesz A.
Neuropsychological deficits in vascular dementia vs. Alzheimer's disease. Frontal lobe deficits prominent in vascular dementia.
Arch Neurol.
1994;
51
1226-1231
100
Mendez M F, Chertier M M, Perryman K M.
Differences between Alzheimer's disease and vascular dementia on information processing measures.
Brain and Cognition.
1997;
34
301-310
101 Oswald W D, Fleischmann U M. Das Nürnberger Altersinventar (NAI). Testzentrale Göttingen 1995
102
Reitan R M, Wolfson D.
Category test and trail making test as measures of frontal lobe functions.
Clinical Neuropsychologist.
1995;
0
50-56
103
Villardita C.
Alzheimer's disease compared with cerebrovascular dementia: neuropsychological similarities and differences.
Acta Neurol Scand.
1993;
87
299-308
104 Reischies F M. Demenzen. In: Karnath HO, Their P (Hrsg.). Neuropsychologie. Heidelberg, Springer 2003: 727-736
105
Bowler J V.
The concept of vascular cognitive impairment.
J Neurol Sci.
2002;
203 - 204
11-15
106
Amenta F, DiTullio M A, Tomassoni D.
The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies.
Clin Exp Hypertens.
2002;
24
697-713
107
Grantham C, Geerts H.
The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease.
J Neurol Sci.
2002;
203 - 204
131-136
108
Erkinjuntti T, Kurz A, Gauthier S. et al .
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
Lancet.
2002;
359
1283-1290
109
Frölich L, Klinger T, Berger F M.
Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease.
J Neurol Sci.
2003;
203 - 204
137-139
110
Moretti R, Torre P, Antonelle R M. et al .
Rivastigmine in subcortical vascular dementia: “an open 22-month study”.
J Neurol Sci.
2002;
203 - 204
141-146
111
Orgogozo J M, Rigaud A S, Stöffler A.
Efficacy and safety of memantine in patients with mild to moderate vascular dementia.
Stroke.
2002;
33
1834-1839
112
Wilcock G, Möbius H J, Stöffler A.
A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
Int Clin Psychopharmacol.
2002;
17
297-305
113
Englund E.
Neuropathology of white matter lesions in vascular cognitive impairment.
Cerebrovascular Diseases.
2002;
13 (Suppl 2)
11-15
114
Hachinski V.
Vascular behavioral and cognitive disorders (Editorial).
Stroke.
2003;
34
2775
115
DelaTorre J C.
Alzheimer disease as a vascular disorder.
Stroke.
2002;
33
1152-1162
116
Royall D R.
Alzheimer disease as a vascular disorder: nosological evidence.
Stroke.
2002;
33
2147
117
DeCarli C.
The role of cerebrovascular disease in dementia.
The Neurologist.
2003;
9
123-136
Prof. Dr. F. Hentschel
Leiter der Abteilung Neuroradiologie, ZI · Fakultät für klinische Medizin Mannheim der Universität Heidelberg
68159 Mannheim
Email: hentsche@zi-mannheim.de